No difference was observed between the three treatment durations in the primary endpoint. Extending nirmatrelvir–ritonavir treatment beyond 5 days resulted in a nominal improvement in the frequency of viral rebound and was generally well tolerated.
The development of glucagon-like peptide-1 (GLP-1)-based therapies for type 2 diabetes and obesity illustrates a remarkable evolution in scientific understanding and therapeutic innovation.1 As the…
Easy-to-read and illustrated information on how different types of anti-HIV drugs work against HIV.
More than half of people who received a pair of broadly neutralising antibodies (bnAbs) plus the immune-modulating drug N-803 (Anktiva) had delayed viral rebound or…
The Pennsylvania Department of Agriculture has called for customers to discard of raw milk after milk from the farm tested positive for Salmonella. The Family…
The West Nile virus has spread into Butler County for the first time this year. According to a news release from the Mercer County Conservation…
Progress towards The Lancet Commission on Global Surgery’s 2030 targets has been too slow and too patchy, particularly in low-income and middle-income countries. The unmet…
Zero HIV Stigma Day Zero is the grassroots campaign mobilising and uniting people across the world to take action against HIV stigma, the primary accelerant…
The risk factors associated with ventilator-associated pneumonia (VAP) in acute ischaemic stroke (AIS) patients who have undergone endovascular therapy have been primarily reported as clinical-related…
Special guest Angela Rasmussen from the University of Saskatchewan in Canada joins Vincent Racaniello for Office Hours to answer your questions about viruses…
